Post-hoc analyses suggested that the reductions in PSA progression and decreased need for secondary therapeutic intervention with ITAS plus zoledronic acid were restricted to tumours with a Gleason score of 8-10 , and that ITAS was better than STAS in tumours with a Gleason score of 7 or lower .